Search
MCC
go.drugbank.com/drugs/DB05282InvestigationalThe product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec. … Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria.
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalBiapenem has been used in trials studying the treatment of various bacterial infections. … It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]
Pentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Pivmecillinam
go.drugbank.com/drugs/DB01605ApprovedInvestigationalPivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.
Bambermycins
go.drugbank.com/drugs/DB11377ExperimentalVet approvedThey are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
Emodepside
go.drugbank.com/drugs/DB11403InvestigationalVet approvedEmodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively
Benzylfentanyl
go.drugbank.com/drugs/DB09182ExperimentalIllicitBenzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. … In 2010 it was removed from the list after it was found to have minimal opioid activity.
Aspartyl-alanyl-diketopiperazine
go.drugbank.com/drugs/DB14940InvestigationalAspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.